

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Hirokazu Shoji
Affiliation	National Cancer Center Hospital
Country	Japan
Major Field	Chemotherapy for gastrointestinal cancer

Educational Background

1996-2000 Department of Biology, Faculty of Science, Tohoku University
2000-2006 Asahikawa Medical University
2015-2018 Degree of Ph.D., Juntendo University

Professional Experience

2010-2015 Resident in National Cancer Center Hospital
2015-2016 Project researcher in National Cancer Center Research Institute
2016-present
Staff physician, Department of Gastrointestinal Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital

Main Scientific Publications

1. Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis. *ESMO Open*. 2025 Jan 3;10(1):104098.
2. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study) *J Immunother Cancer*. 2024 Nov 3;12(11):e010174.
3. Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database. *JCO Precis Oncol*. 2024 Oct;8:e2400284.
4. Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer treatment. *Cell Rep*. 2024 Oct 22;43(10):114774.
5. Targeting SNCA in the treatment of malignant ascites in gastrointestinal cancer. *Transl Oncol*. 2024 Oct;48:102075.
6. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer. *Am J Cancer Res*. 2024 Mar 15;14(3):1174-1189.
7. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. *ESMO Open*. 2024 Feb;9(2):102226.
8. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study. *Int J Clin Oncol*. 2024 Jan;29(1):27-35.
9. Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital. *JAMA Netw Open*. 2023 Sep 5;6(9):e2333188.
10. Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study. *Gastric Cancer*. 2023 Jul;26(4):614-625.